The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.

B lymphocytes must respond to low concentrations of antigen despite having low affinity antigen receptors during the primary immune response. CD19, a B cell-restricted membrane protein of the immunoglobulin superfamily that associates with the antigen receptor complex, may help the B cell meet this requirement. Cross-linking CD19 to membrane immunoglobulin (mIg) lowers, by two orders of magnitude, the number of mIg that must be ligated to activate phospholipase C (PLC) or to induce DNA synthesis. CD19 is coupled, via protein tyrosine kinases (PTKs), to PLC and phosphatidylinositol 3' kinase (PI3' kinase), and it interacts with the Src-type nonreceptor PTK lyn. It also associates with two other membrane proteins, CR2 (complement receptor type 2, CD21), which permits nonimmunologic ligation of CD19, and TAPA-1, a member of the tetraspan family of membrane proteins. CR2 binds fragments of C3 that are covalently attached to glycoconjugates. This indirectly enables CD19 to be cross-linked to mIg after preimmune recognition of an immunogen by the complement system. CR2 also can be ligated by CD23, a lectin-like membrane protein that resides on cells that may present antigen to B cells. TAPA-1 associates with several other membrane proteins on B and T cells, including MHC class II, CD4, and CD8, and it promotes Ca2(+)- and LFA-1-independent homotypic aggregation when ligated directly or indirectly through CD19 or CR2. This may facilitate interaction of the B cell with other cells essential for cellular activation. The formation of this membrane protein complex by representatives of three different protein families helps the B cell resolve its dilemma of combining broad specificity with high sensitivity.

[1]  R. Frade,et al.  EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein. , 1992, Journal of immunology.

[2]  M. Kazatchkine,et al.  Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion , 1991, The Journal of experimental medicine.

[3]  S. Takahashi,et al.  Structure and membrane topology of TAPA-1. , 1991, The Journal of biological chemistry.

[4]  D. Fearon,et al.  Binding of C3b and C4b by the CR1-like site in murine CR1. , 1994, Journal of immunology.

[5]  I. Maclennan,et al.  Recombinant 25‐kDa CD23 and interleukin 1α promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis , 1991, European journal of immunology.

[6]  M. Busslinger,et al.  The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP , 1992, Molecular and cellular biology.

[7]  I. Mellman,et al.  Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes , 1994, Nature.

[8]  D. Fearon,et al.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. , 1992, Science.

[9]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[10]  T. Tedder,et al.  Regulation of the tyrosine kinase-dependent adhesion pathway in human lymphocytes through CD45. , 1993, Journal of immunology.

[11]  P. Roques,et al.  Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. , 1993, Blood.

[12]  D. Fearon,et al.  Tissue-specific phosphorylation of complement receptors CR1 and CR2 , 1986, The Journal of experimental medicine.

[13]  B. Myones,et al.  Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. , 1990, The Journal of biological chemistry.

[14]  J. Gordon,et al.  Inhibition of interleukin 4‐promoted CD23 production in human B lymphocytes by transforming growth factor‐β, interferons or anti‐CD19 antibody is overriden on engaging CD40 , 1991, European journal of immunology.

[15]  D. Fearon,et al.  Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2 , 1989, The Journal of experimental medicine.

[16]  U. Dianzani,et al.  Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages , 1993, European journal of immunology.

[17]  R. Callard,et al.  Inhibition of B cell proliferation with anti‐CD19 monoclonal antibodies: anti‐CD19 antibodies do not interfere with early signaling events triggered by anti‐IgM or interleukin 4 , 1991, European journal of immunology.

[18]  D. Ambrosino,et al.  Proliferation of resting B cells is modulated by CR2 and CR1. , 1989, Immunology letters.

[19]  J. Seehafer,et al.  Evidence that the signal-initiating membrane protein CD9 is associated with small GTP-binding proteins. , 1991, Biochemical and biophysical research communications.

[20]  G. Nemerow,et al.  Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Heyman,et al.  Inhibition of immunological memory and T‐independent humoral responses by monoclonal antibodies specific for murine complement receptors , 1991, European journal of immunology.

[22]  J. Lambris,et al.  Expression of EBV/C3d receptors on T cells: biological significance. , 1993, Immunology today.

[23]  B. Margolis,et al.  Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation. , 1992, The EMBO journal.

[24]  S. Levy,et al.  The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.

[25]  C. Roifman,et al.  CD19 is a substrate of the antigen receptor-associated protein tyrosine kinase in human B cells. , 1993, Biochemical and biophysical research communications.

[26]  N. Thielens,et al.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41 , 1991, The Journal of experimental medicine.

[27]  C. Watts,et al.  Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells , 1994, Nature.

[28]  T. Kinoshita,et al.  Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells. , 1993, International immunology.

[29]  G. Klaus,et al.  The generation of memory cells. I. The role of C3 in the generation of B memory cells. , 1977, Immunology.

[30]  D. Fearon,et al.  Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). , 1989, Advances in immunology.

[31]  D. Montefiori,et al.  CD4‐independent binding of HIV‐1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody , 1992, Clinical and experimental immunology.

[32]  A. DeFranco,et al.  Tyrosine phosphorylation of phospholipase C-gamma 2 upon cross-linking of membrane Ig on murine B lymphocytes. , 1992, Journal of immunology.

[33]  J A Hardin,et al.  Induction of autoreactive B cells allows priming of autoreactive T cells , 1991, The Journal of experimental medicine.

[34]  D. Fearon,et al.  Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Tuveson,et al.  CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. , 1993, Science.

[36]  L. Picker,et al.  Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. , 1994, Blood.

[37]  S. Kingsmore,et al.  Genetic organization of complement receptor-related genes in the mouse , 1989, The Journal of experimental medicine.

[38]  D. Montefiori,et al.  Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. , 1990, Virology.

[39]  R. Brines,et al.  Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. , 1994, Immunity.

[40]  B. Heyman,et al.  In vivo inhibition of the antibody response by a complement receptor- specific monoclonal antibody , 1990, The Journal of experimental medicine.

[41]  H. Kawaguchi,et al.  Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. , 1993, The Journal of clinical investigation.

[42]  C. Janeway,et al.  Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. , 1992, Journal of immunology.

[43]  M. Harnett,et al.  G protein coupling of antigen receptor-stimulated polyphosphoinositide hydrolysis in B cells. , 1988, Journal of immunology.

[44]  S. Kanner,et al.  Tyrosine phosphorylation of CD19 in pre‐B and mature B cells. , 1993, The EMBO journal.

[45]  J. Gordon,et al.  Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor , 1993, European journal of immunology.

[46]  S. Christensen,et al.  Identification of sites for distinct DNA binding proteins including Oct-1 and Oct-2 in the Cr2 gene. , 1992, Journal of immunology.

[47]  M. Kazatchkine,et al.  Evidence for the Role of CR1 (CD35), in addition to CR2 (CD21), in Facilitating Infection of Human T Cells with Opsonized HIV , 1993 .

[48]  T. Schulz,et al.  Growth control of activated, synchronized murine B cells by the C3d fragment of human complement , 1985, Nature.

[49]  J. Bonnefoy,et al.  CD21 is a ligand for CD23 and regulates IgE production , 1992, Nature.

[50]  S. Emr,et al.  Genetic and biochemical studies of protein sorting to the yeast vacuole. , 1993, Current opinion in cell biology.

[51]  M. Holder,et al.  A subset of anti‐CD21 antibodies promote the rescue of germinal center B cells from apoptosis , 1993, European journal of immunology.

[52]  A. Burkhardt,et al.  Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. , 1993, The Journal of biological chemistry.

[53]  D. Tuveson,et al.  Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 , 1991, The Journal of experimental medicine.

[54]  D. Fearon The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. , 1993, Current opinion in immunology.